Guardant Health $GH Q3 earnings: • Revenue up 39% YoY to $265M • Raised 2025 guidance to $965–$970M (+31%) • Oncology tests +40%, Screening revenue up from $1M → $24M! • Gross margin 66% (vs 63%) Shield multi-cancer test launch, FDA submission for Guardant360, & new Quest + ACS partnerships. I mean, come on. That’s pretty good. Shares up 16% after hours as I type.
View on X ↗